On October 13, 2026 Zelluna (OSE: ZLNA), a clinical-stage biotechnology Company pioneering allogeneic, off-the-shelf T-cell receptor-based natural killer (TCR-NK) cell therapies for solid cancers, reported it will publish its financial results for the third quarter of 2026 on Thursday, 5 November 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In connection with the third quarter results, the Company will provide an update on its activities during the quarter, including progress in the ongoing Phase 1 ZIMA-101 study of ZI-MA4-1, Zelluna’s first-in-class MAGE-A4-targeting TCR-NK cell therapy for advanced solid tumours.
The presentation will be available via a live webcast on www.zelluna.com at 09:00 CET on Thursday, 5 November 2026, and participants will be able to submit questions during the presentation. The webcast recording will remain available on the Company’s website after the event.
The quarterly report and presentation materials will be published on the Company’s website at 07:00 CET on Thursday, 5 November 2026, ahead of the webcast.
(Press release, Zelluna Immunotherapy, OCT 13, 2026, View Source [SID1234673376])